These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 10668603)

  • 1. [Neuropsychiatric disorders induced by MDMA ("Ecstasy")].
    Bailly D
    Encephale; 1999; 25(6):595-602. PubMed ID: 10668603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Psychiatric and cognitive long-term effects of ecstasy].
    Høiseth G; Løvåsdal Ø; Titze TK; Bramness JG; Bachs L
    Tidsskr Nor Laegeforen; 2006 Feb; 126(5):596-8. PubMed ID: 16505868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review.
    Montoya AG; Sorrentino R; Lukas SE; Price BH
    Harv Rev Psychiatry; 2002; 10(4):212-20. PubMed ID: 12119307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Psychiatric disorders and consumption of ecstasy drug (MDMA): review of published case reports].
    Bango J; Fadón P; Mata F; Rubio G; Santo-Domingo J
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(4):260-3. PubMed ID: 9807860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion].
    Molero-Chamizo A
    Rev Neurol; 2005 Jul 16-31; 41(2):108-14. PubMed ID: 16028190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
    Karlsen SN; Spigset O; Slørdal L
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of acute psychotic episode after a single dose of ecstasy].
    Vaiva G; Bailly D; Boss V; Thomas P; Lestavel P; Goudemand M
    Encephale; 2001; 27(2):198-202. PubMed ID: 11407274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature.
    Uys JD; Niesink RJ
    Drug Alcohol Rev; 2005 Jul; 24(4):359-68. PubMed ID: 16234132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response.
    Green AR; O'shea E; Colado MI
    Eur J Pharmacol; 2004 Oct; 500(1-3):3-13. PubMed ID: 15464016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ecstasy: are animal data consistent between species and can they translate to humans?
    Easton N; Marsden CA
    J Psychopharmacol; 2006 Mar; 20(2):194-210. PubMed ID: 16510478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use.
    Gouzoulis-Mayfrank E; Fischermann T; Rezk M; Thimm B; Hensen G; Daumann J
    Drug Alcohol Depend; 2005 Jun; 78(3):317-23. PubMed ID: 15893163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.
    Gouzoulis-Mayfrank E; Daumann J
    J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').
    McCann UD; Slate SO; Ricaurte GA
    Drug Saf; 1996 Aug; 15(2):107-15. PubMed ID: 8884162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cerebral hemorrhage and "ecstasy"].
    Schlaeppi M; Prica A; de Torrenté A
    Praxis (Bern 1994); 1999 Mar; 88(13):568-72. PubMed ID: 10235031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
    Parrott AC
    J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the acute subjective effects of MDMA/ecstasy.
    Baylen CA; Rosenberg H
    Addiction; 2006 Jul; 101(7):933-47. PubMed ID: 16771886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?
    Morgan MJ; McFie L; Fleetwood H; Robinson JA
    Psychopharmacology (Berl); 2002 Jan; 159(3):294-303. PubMed ID: 11862362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on Halpern et al. (2011): strengthening the case against functionally significant serotonergic neurotoxicity in human MDMA (ecstasy) users.
    Lyvers M
    Addiction; 2011 Apr; 106(4):787-8. PubMed ID: 21371152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.